載入...
An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavir
BACKGROUND: The World Health Organisation approved boosted atazanavir as a preferred second line protease inhibitor in 2010. This is as an alternative to the current boosted lopinavir. Atazanavir has a lower genetic barrier than lopinavir. We compared the virological outcomes of patients during the...
Na minha lista:
| 發表在: | BMC Infect Dis |
|---|---|
| Main Authors: | , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
BioMed Central
2019
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6434787/ https://ncbi.nlm.nih.gov/pubmed/30909871 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12879-019-3907-5 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|